Order Article Reprints

Driessen CM, Ham JC, te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, et al. Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study). Cancers. 2019; 11(4):551. https://doi.org/10.3390/cancers11040551

Driessen, Chantal M., Janneke C. Ham, Maroeska te Loo, Esther van Meerten, Maurits van Lamoen, Marina H. Hakobjan, Robert P. Takes, Winette T. van der Graaf, Johannes H. Kaanders, Marieke J.H. Coenen, and et al. 2019. "Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study)" Cancers 11, no. 4: 551. https://doi.org/10.3390/cancers11040551

Driessen, C. M., Ham, J. C., te Loo, M., van Meerten, E., van Lamoen, M., Hakobjan, M. H., Takes, R. P., van der Graaf, W. T., Kaanders, J. H., Coenen, M. J. H., & van Herpen, C. M. (2019). Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study). Cancers, 11(4), 551. https://doi.org/10.3390/cancers11040551